Pages
Posts
- MicroDose Therapeutx to Present at the 30th Annual Cowen Healthcare Conference on Tuesday, March 9th
- MicroDose Therapeutx Acquires Epix Pharmaceuticals Portfolio of Compounds for Treatment of Chronic Constipation and Irritable Bowel Syndrome with Constipation (IBS-C)
- MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)
- MicroDose Therapeutx Announces Initiation of Phase 1 Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning
- MicroDose Therapeutx Announces Expansion of Collaboration with Merck & Co., Inc for Dry Powder Inhaler Technology
- MicroDose Technologies Becomes MicroDose Therapeutx: Name Change Reflects Expanded Vision and Opportunities
- MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose’s Electronic Dry Powder Inhaler
- MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
- MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
- MicroDose Technologies Grants Global License to Merck & Co., Inc., for Use of the MicroDose Inhaler with Merck’s Proprietary Products
- MicroDose Technologies Announces Multi-Product Respiratory Collaboration for its Next Generation Inhaler Device
- Innovata and MicroDose Regain Rights to Inhaled Insulin from Bristol-Myers Squibb
- 3M Drug Delivery Systems and MicroDose Technologies, Inc. Team Up to Bring Advanced Electronic Dry Powder Inhaler Technology to Market Collaboration will Provide Fully Integrated Drug Delivery Solutions for the Pharmaceutical and Biotechnology Industries
- University of Pittsburgh receives Department of Defense grant to develop delivery system for nerve agent poisoning antidote
- Bristol-Myers Squibb And QDose Announce Collaboration To Develop Inhaled Insulin For The Treatment of Diabetes
- Microdose Reports Success In First Clinical Trial For Inhaled Insulin Using Novel Microdose Device; Needle-Free Alternative For Diabetes Treatment
- Quadrant Healthcare PLC Joint Venture With Microdose Technologies to Exploit Pulmonary Delivery of Peptides and Proteins